Hisamitsu Pharmaceutical Co., Inc.: Business Overview, Financials & Competitive Analysis
Hisamitsu Pharmaceutical Co., Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Hisamitsu trades at a premium valuation despite modest growth and margin compression, presenting a mixed risk-reward profile for investors. Trailing net profit margin sits at 11.8%, compared with 13.9% a year earlier, with critics highlighting that softer profitability weakens the case for a premium valuation. The company's 4.4%.
What is Hisamitsu Pharmaceutical Co., Inc.'s industry? Hisamitsu Pharmaceutical Co., Inc. (hisamitsu.co.jp) operates in Pharmaceuticals. AskCyborg classifies Hisamitsu Pharmaceutical Co., Inc. under Pharmaceuticals in its company registry.
Hisamitsu Pharmaceutical manufactures and sells pharmaceuticals in Japan, specializing in the niche transdermal drug delivery system (TDS) market. The company is best known for its flagship over-the-counter brand Salo...
Cyborg Score thesis
Hisamitsu trades at a premium valuation despite modest growth and margin compression, presenting a mixed risk-reward profile for...
Read the full analyst-debate transcript →Get the Latest Hisamitsu Pharmaceutical Co., Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeHisamitsu Pharmaceutical Co., Inc. Overview
Pro stress-test →Hisamitsu Pharmaceutical manufactures and sells pharmaceuticals in Japan, specializing in the niche transdermal drug delivery system (TDS) market. The company is best known for its flagship over-the-counter brand Salonpas®, recognized as the world's No. 1 topical analgesic patch. It exports its products to Asia, the United States, and the European area.
Strategic Profile
Pro stress-test →The company operates a single business segment focusing on medical and general pharmaceuticals both in Japan and overseas, marketing drugs under the Salonpas, Nobinobi/Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs. As of February 19, 2026, Hisamitsu Pharmaceutical operates as a subsidiary of Taiyo Kosan Co., Ltd. The company maintains a strong position in OTC pain relief with established brand recognition globally.
Competitive Landscape
Pro stress-test →Hisamitsu competes in the topical medication market with brands like Salonpas, Nobinobi/Salonsip, Butenalock, and Mohrus. The company faces competition from global OTC pharmaceutical manufacturers and other topical pain relief product makers, though its Salonpas brand maintains market leadership in topical analgesics. The company's premium valuation reflects its established market position but faces headwinds from slow earnings growth forecasts.
Industry Context
Hisamitsu Pharmaceutical Co., Inc. operates in Pharmaceuticals.
Key facts
Founded: 1847 · Headquarters: Tosu, Japan · Revenue: ¥163.0B (FY 2026 trailing 12-month) · Market cap: ¥423.01B (~$2.67B USD, April 2026)